Consonance Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Consonance Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,152,543	Closed	-$37M	–	28
2016 Q4	$37M	Buy	1,152,543 +396,269	+52%	+$16.9M	4.06%	12
2016 Q3	$37.8M	Buy	+756,274	New	+$31.4M	3.64%	13
2016 Q2	–	Sell	-746,734	Closed	-$49.2M	–	25
2016 Q1	$49.2M	Buy	+746,734	New	+$39M	7.44%	5
2014 Q4	–	Sell	-195,340	Closed	-$13.5M	–	27
2014 Q3	$13.5M	Buy	+195,340	New	+$10.4M	1.85%	19

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Consonance Capital Management's MACK Position: Q1 2017 in Review

Consonance Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 1,152,543 shares — an estimated $37M sold.

Consonance Capital Management first reported a position in MACK in Q3 2014 and held it in 4 quarters. The position peaked at $49.2M in Q1 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

Consonance Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Consonance Capital Management sold 1,152,543 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $37M.
Consonance Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 4 quarters.
Consonance Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $49.2M in Q1 2016.
116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Consonance Capital Management's 13F filing for Q1 2017, filed 15 May 2017.